Escalating Plasmodium falciparum K13 marker prevalence indicative of artemisinin resistance in southern Rwanda

Antimicrob Agents Chemother. 2024 Jan 10;68(1):e0129923. doi: 10.1128/aac.01299-23. Epub 2023 Dec 11.

Abstract

In 2023, we updated data collected since 2010 on Plasmodium falciparum K13 and MDR1 drug resistance markers in Huye district, southern Rwanda. Artemisinin resistance-associated PfK13 markers occurred in 17.5% of 212 malaria patients (561H, 9.0%; 675V, 5.7%; and 469F, 2.8%), nearly double the frequency from 2019. PfMDR1 N86, linked with lumefantrine tolerance, was close to fixation at 98%. In southern Rwanda, markers signaling resistance to artemisinin and lumefantrine are increasing, albeit at a relatively slow rate.

Keywords: Plasmodium falciparum; Rwanda; artemisinin; malaria; multi drug resistance.

MeSH terms

  • Antimalarials* / pharmacology
  • Antimalarials* / therapeutic use
  • Artemisinins* / pharmacology
  • Artemisinins* / therapeutic use
  • Drug Resistance / genetics
  • Humans
  • Lumefantrine / therapeutic use
  • Malaria, Falciparum* / drug therapy
  • Malaria, Falciparum* / epidemiology
  • Plasmodium falciparum / genetics
  • Prevalence
  • Protozoan Proteins / genetics
  • Protozoan Proteins / therapeutic use
  • Rwanda / epidemiology

Substances

  • Antimalarials
  • artemisinin
  • Artemisinins
  • Lumefantrine
  • Protozoan Proteins